# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...
Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:CI) with a Overweight and maintains $400 price target.
RBC Capital analyst Ben Hendrix reiterates Cigna (NYSE:CI) with a Outperform and maintains $384 price target.